comparemela.com

Latest Breaking News On - மருத்துவ அமைப்பு ஹோல்டிங்ஸ் வரையறுக்கப்பட்டவை - Page 1 : comparemela.com

Starting its Industrial Investment in Biotech Companies, China Medical System (0867 HK) has Accelerated its Flywheel of Innovation

Starting its Industrial Investment in Biotech Companies, China Medical System (0867 HK) has Accelerated its Flywheel of Innovation
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

China Medical System (0867 HK) Has Accelerated Its Flywheel Of Innovation

Tuesday, 27 April 2021, 6:03 am Starting Its Industrial Investment In Biotech Companies, China Medical System (0867.HK) Has Accelerated Its Flywheel Of Innovation HONG KONG, Apr 26, 2021 - (ACN Newswire) - China Medical System Holdings Limited (0867.HK) ( CMS or the Company ) has been active in the market this year. From the acquisition of Luqa to enter the medical aesthetic market early this year, the Company has attracted the attention of the market. Recently, it has announced the series of agreement signed with Trinomab Biotech Co., Ltd. ( Trinomab ). CMS will make equity investment in Trinomab, and establish a joint venture (the Joint Venture ) with Trinomab, contributed with cash and related products

China Medical System (0867 HK) Accelerating Development and Stepping to New Heights, Driven by Innovation

China Medical System (0867.HK) Accelerating Development and Stepping to New Heights, Driven by Innovation HONG KONG, Apr 05, 2021 - (ACN Newswire) - As the earnings season arrives, listed pharmaceutical companies are attracting much attention. China Medical System Holdings Limited (CMS, or Company) has released its annual results, with both revenue and profit higher than market expectations. According to its 2020 earnings results, turnover is up by 14.4% to RMB6.946 billion; net profit up by 30.7% to RMB2.556 billion; basic earnings per share up to RMB1.024, with a proposed final dividend of RMB0.20 per share. In the past, influenced by expectations of the effects of China s centralized procurement policy and the Company s product transition, CMS s valuation in the capital market was once under pressure, but with the Company s strategic transformation from a CSO to an innovative pharmaceutical company, coupled with its own solid business growth, its share price has gained a signif

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.